Two classes of GGAA-Microsatellites in a Ewing Sarcoma Context

November 1, 2017

In a study published in PLOS ONE, researchers describe two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma. Ewing sarcoma is the second most common pediatric bone malignancy. It is initiated by chromosomal translocation t(11;22)(q24;q12), which creates the fusion protein and oncogenic driver EWS/FLI.

“The work to understand the subtleties of how the EWS/FLI and GGAA-microsatellites interact to drive oncogenesis is foundational to our ability to develop new therapeutics against transcription factor-driven cancers,” says Stephen Lessnick, MD, PhD, director of the Center for Childhood Cancer and Blood Diseases at Nationwide Children’s and senior author of the publication. “Here, we sought to define GGAA-microsatellites in a Ewing sarcoma context and understand their role across the genome.”

In their work, Dr. Lessnick and his team used bioinformatics analysis of experimental data in an unbiased genome-wide approach. Then, they computationally linked bound microsatellites to adjacent EWS/FLI regulated genes. That data revealed two distinct types of GGAA-microsatellites: “promoter-like” (close-range) and “enhancer-like” (long-range).

According to the study, EWS/FLI binding and gene activation at promoter-like microsatellites is highly dependent on the length of GGAA motifs.

At long range, enhancer-like microsatellites demonstrate length-dependent EWS/FLI binding, but the researchers found minimal correlation for activation and none for repressed targets. Here, the number of GGAA-motifs positively correlates with EWS/FLI binding, but not with gene expression.

Further investigation into how EWS/FLI associates with GGAA-microsatellites to drive transcription was the subject of a recent study published in Proceedings of the National Academy of Sciences. Both studies highlight the importance of microsatellite length in oncogenic function.

“Microsatellite length and location appears to be essential for EWS/FLI to activate the oncogenic gene targets,” says Dr. Lessnick. “Our results have revealed and characterized two classes of GGAA-microsatellites that suggest unique interactions and distinct regulatory mechanisms for distance-dependent activation and repressions. This characterization contributes insight into EWS/FLI transcription factor biology and clarifies the role of GGAA-microsatellites on a global genomic scale.” 

About Nationwide Children's Hospital

Named to the Top 10 Honor Roll on U.S. News & World Report’s 2023-24 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit free-standing pediatric health care systems providing unique expertise in pediatric population health, behavioral health, genomics and health equity as the next frontiers in pediatric medicine, leading to best outcomes for the health of the whole child. Integrated clinical and research programs, as well as prioritizing quality and safety, are part of what allows Nationwide Children’s to advance its unique model of care. Nationwide Children’s has a staff of more than 14,000 that provides state-of-the-art wellness, preventive and rehabilitative care and diagnostic treatment during more than 1.7 million patient visits annually. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s physicians train the next generation of pediatricians and pediatric specialists. The Abigail Wexner Research Institute at Nationwide Children’s Hospital is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities. More information is available at NationwideChildrens.org.